Lexeo Therapeutics (LXEO) Income from Continuing Operations (2022 - 2026)

Lexeo Therapeutics has reported Income from Continuing Operations for 5 years, with the latest figure at 20196000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 38.16% year-over-year to 20196000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 89562000.0 (up 18.06% YoY) and the FY2025 annual result came in at 222062000.0, down 125.83% from the prior year.
• Income from Continuing Operations advanced to 20196000.0 in Q1 2026 per LXEO's latest filing, from 22980000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 13441000.0 in Q2 2023 and troughed at 32656000.0 in Q1 2025.
• A 5-year average of 21238400.0 and a median of 20283000.0 in 2025 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations sank 82.73% in 2024, then soared 38.16% in 2026.
• Over 5 years, Income from Continuing Operations stood at 14577000.0 in 2022, then rose by 2.68% to 14187000.0 in 2023, then sank by 82.73% to 25924000.0 in 2024, then increased by 11.36% to 22980000.0 in 2025, then climbed by 12.11% to 20196000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 20196000.0, 22980000.0, and 20283000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.